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Abstract
Background: Imbalance in lipid metabolism and membrane lipid homeostasis has been observed in numerous
diseases including heart failure and cardiotoxicity. Growing evidence links phospholipid alterations especially
cardiolipins (CLs) to defects in mitochondrial function and energy metabolism in heart failure. We have shown
recently that doxorubicin cardiotoxicity is more severe in male than female Wistar rats. We aimed to study whether
this sex specificity is linked to differences in cardiac phospholipid profiles.
Results: Adult male and female rats were injected 2 mg/kg doxorubicin weekly for 7 weeks. Cardiac phospholipid
molecular species were determined by liquid chromatography coupled with mass spectrometry fragmentation (LC)/
MSn. Sex difference in phosphatidylethanolamine and phosphatidylcholine species containing docosahexaenoic and
docosapentaenoic acyl chains was observed, females having more than males. In both sexes, doxorubicin induced an
important loss of the main CL(18:2)4, while the level of monolysocardiolipin MLCL(18:2)3 remained stable. However, a
severe remodelling appeared in treated rats with the longest CL acyl chains in doxorubicin-treated females, which
might compensate for the loss of tetra-linoleoyl CL. The level of oxidized cardiolipin was not particularly increased after
doxorubicin treatment. Finally, expression of genes involved in the biosynthesis of fatty acid appeared to be decreased
in doxorubicin-treated males.
Conclusions: These results emphasize for the first time the cardiac remodelling in the phospholipid classes after
doxorubicin treatment. These observations suggest that doxorubicin has a sex-specific impact on the heart
phospholipidome especially on cardiolipin, an essential mitochondrial lipid. Further studies are needed to
better understand the roles of lipids in the anthracycline cardiotoxicity and sex differences, but phospholipid
cardioprotection seems a valuable new additive therapeutic strategy for anthracycline cardiotoxicity.
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Background
Doxorubicin (DOXO), a widespread anti-cancer agent,
has clinical limited use due to important deleterious
cardiac side effects that ultimately lead to heart failure
(HF). How anthracyclines induce both anti-cancer activity
and cardiotoxicity are not completely understood [1].
Numerous studies have shown the interaction of doxo-
rubicin with membranes, particularly cardiolipin (CL),
causing membrane fluidity alteration and enzyme activity
deficiency [2–4]. We have recently observed that after
7 weeks of doxorubicin treatment, male rats but not
females had high mortality rate, signs of heart failure, and
altered mitochondrial function, and we identified a signifi-
cant decrease in total cardiolipin content specifically in
the heart of treated males [5].
Phospholipids (PLs), a fundamental class of biological
compounds, are the main component of membranes
which represents a biological and physical barrier but also
a site for interaction and signal transduction. Fatty acid
(FA) composition of PL influences membrane characteris-
tics such as membrane fluidity, microdomain formation,
transport system, and membrane-bound enzyme activities
(for review, see [6]). Obviously, deregulation of PL is in-
volved in numerous diseases such as cancer, neurological
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disorders, hepatic disorders, and cardiovascular diseases
(reviewed in [7, 8]).
Cardiolipin, a signature PL of the inner membrane
of the mitochondria (around 20 % of the lipid com-
position), is involved in numerous functional and
structural features of membrane-bound mitochondrial
proteins and is linked to important mitochondrial
processes, including apoptosis, mitochondrial dynamics,
contact sites formation and assembly, and function of
mitochondrial membrane proteins for an effective oxi-
dative phosphorylation (reviewed in [9–12]). CL is a
unique dimeric phospholipid containing two phospha-
tidyl moieties bridged by a glycerol and four fatty acyl
chains. The FA composition is also highly specific
and is predominantly composed of 18:2 acyl chains
with tetra-linoleoyl cardiolipin (L4CL) being the most
abundant [13]. CL composition depends on de novo
synthesis of nascent CL followed by complex pro-
cesses of acyl chain remodelling. The fatty acyl chain
composition of CL is critical for mitochondrial func-
tion and cardiac pathology. Alteration in CL content
and composition has been associated with numerous
disorders like diabetes, thyroid status, aging, and
heart failure [14].
HF is characterized by the inability of the heart to ful-
fill the metabolic requirements of the organism. Among
the characteristics of HF, the state of energy depletion
[15, 16], alterations of the mitochondrial function, and
biogenesis [17] have been well described, but changes in
cardiac PL composition are less addressed. However, car-
diolipin may play a role in mitochondrial alterations in
heart failure [10]. Indeed, decreased cardiolipin content,
altered cardiolipin synthesis and remodelling [18], reduc-
tion in 18:2 CL species [10, 18, 19], and modified expres-
sion or activity of cardiac biosynthesis enzymes [20]
have been reported in numerous diseases. The import-
ance of CL in heart failure is exemplified by the Barth
syndrome, a severe X-linked genetic disorder which is
characterized by CL alterations, mitochondrial defects,
and heart failure and which results from mutations in
the Tafazzin gene, an acyltransferase involved in CL
remodelling [21]. Finally, CLs are susceptible to oxida-
tive damages because they are present in the mitochon-
dria which are the main source of reactive oxygen
species (ROS) and because they contain double bonds
that are susceptible to oxidation. CL oxidation has been
shown to induce decreased activity and organisation of
respiratory chain complexes and to favor apoptosis (for
review, see [11]).
As we have observed, a decrease in total cardiolipin
content in treated males but no females; the objective
of the present study was thus to explore in more de-
tail the cardiac phospholipidome after doxorubicin
treatment in adult rats and to understand whether CL
remodelling participates in the sex-specific cardiac
alterations.
Methods
An expanded method section is available in the Additional
file 1.
Doxorubicin animal model
A chronic model of doxorubicin [22] by weekly intraven-
ous injection of 2 mg/kg doxorubicin or saline solution
during 7 weeks in 11-week-old male and female Wistar
rats (Janvier Labs) was chosen as previously described
[23]. Animal experimental procedures were approved by
the Animal Ethics Committee of Paris Sud University.
Investigations were done in accordance with European
Community legislation relating to the care and use of ani-
mals (Directive 2010/63/EU) and the corresponding French
legislation (French decree 2013-118 du 1er février 2013).
Lipid extraction
A Folch method [24] was used to extract the lipids from 10
to 20 mg of heart homogenized in phosphate-buffered
saline (PBS). Each group was composed of four animals;
one technical repeat was done for a non-treated male and
a doxorubicin-treated male. Total lipids were extracted by
adding 1.5 mL of methanol and 3 mL of chloroform to the
tissue suspension. After centrifugation at 1000g for 10 min,
the lower phase containing total lipids was collected and
evaporated to dryness at room temperature under nitrogen
gas. The samples were resuspended in 100 μL of chloro-
form per 10 mg of heart and subsequently analyzed.
Cardiolipin oxidation
Cardiolipins were oxidized following the method of
Paradies [25]. Briefly, cardiolipins in PBS were mixed in
1 mL of oxygenated buffer containing 20 μM ferrous
sulfate, 120 μM ADP, and 200 μM ascorbic acid for
15 min at 37 °C before being extracted by a Folch
method.
Phospholipid analysis
For the phospholipid analysis, each sample was dupli-
cated, except the technical repeat for a non-treated male.
Chromatographic system from Thermo Fisher Scientific
included a Dionex U 3000 RSLC system with two quater-
nary pumps, an autosampler, and a column oven. The
RSLC system was coupled online to a charged aerosol
detector Corona CAD Ultra for the quantitative part of
the study and a LTQ Orbitrap Velos Pro for the lipidomic
study (all from Thermo Fisher).
Liquid chromatography
The separation of lipids was carried out on a PVA-Sil
column (150 × 2.1 mm I.D., 120 A) (YMC Europe GmbH)
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with a 10 × 2 mm guard column packed with the same
material both supplied by Interchim. The column
temperature was thermostatically controlled at 35 °C.
Chromatographic method was inspired from the method
developed by Imbert et al. [26]. The flow rate was set at
400 μL/min, and a sample volume of 5 μL was injected.
The mobile phase compositions were identical. An isopro-
panol phase (D) has been added to rinse the RSLC system.
The solvent program has been modified as follows: the
Corona CAD nebulizer was set at a temperature of 30 °C
and the nitrogen pressure was set at 5 bar (Table 1).
The LC effluent was split after the analytical column
with aid of a tee; thus, 250 μL/min entered to the Corona
CAD and 150 μL/min entered the mass spectrometer. To
increase the flow entering the Corona CAD and maintain
good aerosol stability, absolute ethanol was added with a
second mixing tee with a flow of 200 μL/min.
Mass spectrometry
The LTQ Orbitrap Velos Pro is equipped with an H-ESI
II probe. Spray voltage was set at 3.3 kV. Heater
temperature of the probe was set at 200 °C. Sheath gas,
auxiliary gas, and sweep gas flow rates were set at 20, 8,
and 0 (arbitrary unit), respectively. Capillary temperature
was set at 325 °C and S-lens RF level at 60 %. Analysis
was performed in negative mode to obtain structural
nformation on phospholipids fatty chains. This mass
spectrometer is equipped with two analyzers: a double
linear ion trap (LTQ) for fragmentation at low resolution
and an orbital trap for high-resolution detection. The
detection was performed either in full mass spectrom-
etry (MS) scan with 100,000 resolution and data depend-
ant MS2 and MS3 with collision-induced dissociation in
the CID fragmentation (collision energy set at 35).
Phospholipid species identification
The chromatographic method used separates the phos-
pholipids by polar head. Retention time is a crucial in-
formation for polar head identification and compared to
commercial standards. Then, species can be observed
under each chromatographic peak. PL identification was
performed as described [27] using high-resolution mass
detection in full scan mode and MS2/MS3 fragmentation
in data dependant mode. MSn fragmentation has not
always been performed by the instrument due to very
small amount of some ions. When no MSn data is avail-
able, PLs are mentioned as, e.g., PL(34:1). Otherwise, PL
are mentioned as, e.g., PL(16:0-18:1). Sn1 and sn2 pos-
ition of the acyl chains were not determined. Oxidized
cardiolipin identification was performed as described by
Kim et al. [28, 29].
Phospholipid species representation
Total phospholipid amount was determined with Corona
CAD detection by calculating the concentration of each
PL class (in micrograms per milliliter) compared to cali-
bration ranges of commercial standards. PL species in-
tensities were determined by taking the mean relative
intensity of m/z ions over the chromatographic peak of
each PL class.
2D separation of CL
The sample’s cardiolipin was collected from 11 to 12 min,
dried over nitrogen, and dissolved in 2D phase mobile (2-
propanol:water:triethylamine:acetic acid 45:5:0.25:0.25). A
Dionex C18 column (Acclaim RSLC 120, 2.2 μm, 120 Å,
2.1 × 150 mm) was used under isocratic solvent condition.
The column temperature was thermostatically controlled
at 40 °C. Flow was maintained at 200 μL/min on a Dionex
U 3000 RSLC system, and MS and MS/MS acquisitions
via LTQ Orbitrap Velos Pro were performed on the most
abundant mass ions.
Statistical analysis
MS raw data were submitted to chromatogram builder,
alignment and gap filling using the MzMine 2.10 LC/MS
toolbox [30]. SIMCA-P 12.0 was used to analyze the
data generated by mass spectrometry (principal compo-
nent analysis (PCA) and OPLS-DA). Data are expressed
as mean ± SEM. Two-way ANOVA (homogenous
variance verified by Levene test for all parameters ex-
cept Cds1 and Acsl1) was used to study the global
effect of sex and treatment, followed by Student-
Newman-Keuls post hoc test to determine individual dif-
ferences. Statistical significance for doxorubicin effect was
defined as * for p < 0.05, ** for p < 0.01, and *** for p < 0.001
and for sex effect as § for p < 0.05, §§ for p < 0.01, and §§§
for p < 0.001.
Table 1 Chromatographic program with the following mobile
phase compositions: mixture of heptane and isopropanol 98:2
(v/v) (phase A); mixture of chloroforme and isopropanol 65:35
(v/v) (phase B); mixture of methanol and water 95:5 (v/v)
(phase C); isopropanol (phase D)
Time A B C D
0 98 2 0 0
2 98 2 0 0
8 12 88 0 0
22 0 60 40 0
26 0 60 40 0
27 0 0 0 100
29 0 0 0 100
30 98 2 0 0
44 98 2 0 0
All A, B and C mobile phases also contain acid acetic 1% (v/v) and
triethylamine 0.08% (v/v)
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Results
Doxorubicin treatment affects cardiac phospholipid
content differently between males and females
Doxorubicin treatment induces a life-threatening car-
diotoxicity with altered mitochondrial function. We
have shown recently that males were less protected
against DOXO cardiotoxicity and that cardiolipin con-
tent was differently altered in males and females under
DOXO. To evaluate the cardiac phospholipid profile
in doxorubicin-mediated cardiotoxicity, we performed
lipidomic analysis of the hearts from male and female
rats treated or not with doxorubicin for 7 weeks. To
separate PL classes, we used a PVA-Sil column with a
gradient program, used CAD for PL quantification and an
ESI hybrid mass spectrometer (ESI/MS) to characterize
the PL (Fig. 1a). The level of pooled main phospholipids
(CL/phosphatidylinositol (PI)/phosphatidylethanolamine
(PE)/phosphatidylserine (PS)/phosphatidylcholine (PC))
was similar in basal condition for both sexes; however,
after doxorubicin treatment, cardiac phospholipid con-
tent was decreased only for the males (Fig. 1b). Principal
component analysis of variables from LC-MS/MS analysis
Fig. 1 Doxorubicin and sex effect on cardiac phospholipids. a A representative phospholipid class separation (first dimension) obtained by LC-
ESI/MS (TIC, total ion chromatogram) and Corona CAD detection; asterisk is for unspecific peak. b Phospholipid (CL/PI/PE/PS and PC) contents
measured from the HPLC Corona CAD detection in ventricles of 7 weeks doxorubicin-treated rats. c Score plot obtained by principal component
analysis (PCA) of m/z ions from cardiac tissue analysis generated by LC-ESI/MS. Each sample (four per group) was duplicated
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showed that non-treated animals clearly separate from
doxorubicin-treated animals (21.2 % of variance explained
on principal component PC1), and males trend to separate
from females (10.9 % of variance explained on PC3)
(Fig. 1c). These analyses are in accordance with our pre-
vious results demonstrating sex difference in DOXO
cardiotoxicity [5]. The MS data were then subjected to
orthogonal partial least squares discriminant analysis
(OPLS-DA) in order to detect the variables which char-
acterise the most important changes between male and
female in non-treated condition or after doxorubicin
treatment and the effect of treatment in each sex
(Additional file 1: Table S1). We found mainly discrimin-
ating PE and CL species and less species of PC, phosphati-
dylglycerol (PG), and monolysocardiolipin (MLCL). Of
note was the number of PL species with longer chains
(≥20 carbons) showing sex differences. These results
underline variation of cardiac phospholipid composition
after doxorubicin treatment and differently according to
sex.
As PE and PC are the most abundant cardiac phospho-
lipids (Fig. 1a), we then analyzed in more detail their fatty
acyl chain composition. As shown in Fig. 2a, important
sex differences are present at baseline and after DOXO for
Fig. 2 Doxorubicin and sex effect on cardiac PC and PE profile. a Analysis of m/z intensity of PC species by LC-ESI/MS (mean ± SEM of four rats per
group, duplicated samples) with sex difference after doxorubicin treatment. b Analysis of m/z intensity of PE species by LC-ESI/MS with sex difference
after doxorubicin treatment. c Doxorubicin effect (without sex difference) of m/z intensity of PC and PE. d No significant difference between groups of
m/z intensity of PC and PE
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PC containing docosapentaenoic (22:5) and docosahexae-
noic (22:6) acyl chains. Interestingly, the same profile was
observed for the PE species with similar acyl chains
(Fig. 2b). In contrast, PE and PC consisting of linoleoyl
acyl chain (18:2) combined with saturated palmitic or ste-
aric acyl chain did not present sex difference but were
strongly reduced by DOXO treatment in both sexes
(Fig. 2c). Finally, two other PE and PC species presented
no change among sex and treatment (Fig. 2d). These re-
sults underline a great variability of PE and PC species
and show that the level of the different species may vary
according to doxorubicin and/or sex.
Sex-specific cardiolipin remodelling after doxorubicin
treatment
As we previously showed, a decrease in CL content par-
ticularly in DOXO-treated males [5], analysis of cardioli-
pin species was necessary to dissect this deficit. Because
of the four acyl chains, a great variety of CL was identi-
fied (Additional file 1: Table S2). A marked reduction of
the most abundant CL: the tetra-linoleoyl (18:2)4 (L4CL)
was observed after DOXO treatment but with no differ-
ences between sex (Fig. 3a). In contrast, almost all the
other CL species were more abundant after DOXO
treatment, and even more for the females (Fig. 3b),
which may compensate for the tetra-linoleoyl CL loss.
Doxorubicin induced a profound remodelling of CL
species with longer acyl chains (≥20 carbons). Some car-
diolipin species were detected only after doxorubicin
(Fig. 3c). Moreover, sex difference occurred only after
doxorubicin treatment, as no basal male-female differ-
ence was observed (Fig. 3a–c). These results showed the
complexity of CL profile in the heart. As summarized in
the Table 2, the cardiotoxic treatment induced a severe
remodelling in the CL family and the formation of new
CL species and differentially between sex, as shown by
the interaction between sex and doxorubicin treatment
specific for cardiolipin.
Low level of oxidized cardiolipin after 7 weeks of
doxorubicin treatment in males
Because cardiolipin oxidation has been observed in
different pathologies and doxorubicin is a well-known
stress oxidant inducer, we analyzed CL oxidation.
Based on a previous study [31], we performed a two-
dimensional HPLC coupled to MS to separate oxidized
CL from non-oxidized counterparts. As a positive con-
trol, we oxidized standard CLs (CLox) with oxygenated
buffer containing ferrous sulfate, ADP, and ascorbic
acid. We verified that the CLox were part of the cardi-
olipin peak in the first dimension (Additional file 1:
Figure S1A). In the second dimension, CLox were re-
solved into multiple peaks (Additional file 1: Figure S1B
and S2A, B). The tetra-linoleoyl (m/z 1447.9) CL was
oxidized in various species (i.e., m/z 1463.9, 1479.9,
1495.9, and 1511.9 corresponding to the addition of 1 to
4 oxygens). In the heart sample of non-treated or
doxorubicin-treated males, we could detect CLox; how-
ever, the level of these species were very low (<0.5 %;
Fig. 4a, b). Even if the percentage of CL + 4[O] and CL +
5[O] appeared slightly more important in the DOXO-
treated males than in the non-treated ones, the global
level of oxidation seemed rather minimal. For this reason,
we did not analyze the CLox in the female animals. Over-
all, these results suggest that oxidative damage to cardiac
cardiolipin is not largely found after 7 weeks of doxorubi-
cin treatment. These data are in accordance with our pre-
vious results showing that global protein carbonylation
was comparable in the heart of males and females treated
or not with doxorubicin [5].
Cardiolipin biosynthesis is altered in males and females
treated with doxorubicin
CL biosynthesis is a multi-step process and the nascent
CL from phosphatidyl glycerol (PG) is remodeled by dif-
ferent enzymes to form a “mature” CL (Additional file 1:
Figure S3). Another important remodelling pathway in-
cludes the conversion of MLCL to CL. Moreover, a link
has been made between the content of PL(18:2) and the
poly-unsaturated FA metabolism [32]. Thus, we analyzed
the PG and MLCL cardiac content. We identified only
eight PG species (Additional file 1: Table S2 and Fig. 5a).
In contrast to PE and PC, we did not detect PG contain-
ing long acyl chains. However, similar to PE and PC, PG
consisting of linoleoyl acyl chains (18:2) combined with
saturated palmitic or stearic acyl chains did not present
sex difference but were strongly reduced by doxorubicin
treatment in both sexes (Fig. 5a). To note, PG (16:0-18:1)
was specifically upregulated in doxorubicin-treated females.
Concerning MLCL, we identified 26 different members
(Additional file 1: Table S2) with the most abundant form:
the tri -linoleoyl MLCL (18:2)3 (Fig. 5b). Surprisingly, the
level of this MLCL did not vary between groups. However,
similar to CL, doxorubicin induced a sex-specific remodel-
ling of MLCL species with longer acyl chains (Fig. 5c).
Finally, the expression of key genes involved in
phospholipid, FA metabolism, and CL remodelling was
assessed (Fig. 6). No significant change was observed
for the plasma membrane fatty acid transport protein
Cd36, CDP-diacylglycerol synthase2 (Cds2), Acyl-CoA:
lysocardiolipin acyltransferase-1 (Alcat1), and Δ5-desatur-
ase expression among the four groups. A lower expression
of Cds1 was observed in non-treated females compared to
males. Doxorubicin induced a decrease in expression of
acyl-CoA synthetase long-chain family member 1 Acsl1,
Cds1, cardiolipin synthase1 (Crls1), Tafazzin, Δ6-desatur-
ase, and Elongase5 for males. Regarding treated females,
decreased expression was similar as males for Cds1 and
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Fig. 3 Sex-specific cardiolipin remodelling after doxorubicin treatment. a Cardiolipin spectra obtained by LC-ESI/MS from male and female
rats treated for 7 weeks with doxorubicin (DOXO) or saline (NT). Insert panels: mean intensity of CL(18:2)4 and CL(18:2)3(22:6). b Identified
cardiolipin m/z intensity (mean ± SEM of four rats per group, duplicated samples). c Non-identified cardiolipin intensity mainly present in
doxorubicin-treated rats
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Crl1 and less important for the other genes, except for
Δ6-desaturase and Elongase5 as no reduction was ob-
served. Taken together, these results show a sex-specific
remodelling of MLCL species with longer acyl chains in
females and a more reduced expression of enzymes in-
volved in fatty acid synthesis pathway in doxorubicin-
treated males than females (Additional file 1: Figure S3).
Discussion
In support of our previous work showing male-specific
doxorubicin cardiotoxicity [5], this study describes for the
first time the cardiac phospholipidome after doxorubicin
treatment in both sexes. The role of phospholipids in the
heart and the sex impact has been poorly explored, despite
essential structure and signal transduction functions. After
chronic doxorubicin treatment in male and female adult
rats, we characterized doxorubicin and sex-specific
phospholipid remodelling as best discriminating compo-
nent by PCA.
From the 1980s, alterations of heart phospholipid con-
tent have been described in many cardiovascular diseases.
Decrease in linoleic acid and increases in arachidonic and
docosahexaenoic acid have been observed in myocardial
phospholipids of rats and cats after TAC [33] and chronic
coronary artery ligation [34]. A link has been made
between alteration in PL and the severity of heart failure.
PE, PC, PI, and PS, the main classes of PL, are present in
different membranes of cardiomyocytes (sarcolemma, RS,
mitochondria). These phospholipids are involved in various
signal transduction pathways; they can be split by phospho-
lipases into inositol triphosphate and diacylglycerol that
function as second messengers. As we used heart tissue, we
cannot discriminate the sarcolemma PL from the intracel-
lular membrane organelles PL. Additional investigations are
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needed to determine the exact composition of the different
membrane organelles. Thus, we will focus the discussion
on CL because there are specific to the inner mitochondrial
membrane and appears critical for mitochondrial function
and cardiac pathology [9].
Several studies have highlighted the essential role of
the mitochondria in heart failure and in anthracycline
cardiotoxicity [5, 35–37]. The energetic depletion linked
to mitochondrial defect is often related to a reduction in
mitochondrial mass. However, when maximal oxygen
consumption decreased and activities of key enzymes of
energy metabolism (e.g., CS, CK, and COX) remained
stable with no change in protein level of the peroxisome
proliferator-activated receptor gamma co-activator 1
(PGC-1), the orchestrator for mitochondrial biogenesis,
mitochondrial energetic deficiency has been suggested to
be linked to a disruption of local environment [5, 38]. One
key parameter for optimal and functional mitochondria is
Fig. 4 Low level of oxidized cardiolipin after 7 weeks of doxorubicin treatment in males and females. a Second dimension chromatographic
separation of cardiolipin collected on the first dimension: full scan analysis by LC-ESI/MS of one non-treated male and one doxorubicin-treated
male. b Relative representation of oxidized cardiolipin
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cardiolipin. Not surprisingly, CL alterations such as con-
tent, distribution, oxidation, and acyl chain composition
have been reported in many diseases including Barth
syndrome, Parkinson disease, and heart failure [14]. As
previously described [13], the main molecular species of
cardiolipin is the L4CL (18:2)4, representing around 55 %
of total CL in male and female rat hearts. This level was
reduced to 35 % in both sexes after doxorubicin treat-
ment. Decrease of linoleic acid in cardiolipin has also been
observed in ischemic, dilated, diabetic cardiomyopathies,
and in senescent heart [20, 39, 40]. Moreover, most of the
time, increase in 22:6 docosahexaenoic acid was noticed
[20, 39, 40]. Hearts from doxorubicin-treated males
presented an increase in CL containing 22:6 acyl chain,
and this was highly exacerbated for the females. Moreover,
some CL species appeared in DOXO-treated animals that
were not present in controls also with a significantly
higher content in females, indicating the occurrence of an
alternate form of CL remodelling after DOXO treatment.
Such a cardiac long acyl chain PL remodelling has been
reported in heart failure and aging [32, 41]. One important
point is that all these studies showing acyl chain CL re-
modelling were obtained in male animals/patients, and no
comparison was made with females. This remodelling in
males might be a compensatory mechanism but still
insufficient to correct CL alterations. Because the total CL
Fig. 5 Doxorubicin and sex effects on cardiac PG and MLCL profiles. a Analysis of m/z intensity of PG species by LC-ESI/MS (mean ± SEM of four
rats per group, duplicated samples). b Analysis of m/z intensity of MLCL species by LC-ESI/MS
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level was not reduced in DOXO-treated females and be-
cause mitochondrial function was not altered [5], it can be
inferred that the significant increase in longer acyl chain
(20:2, 20:3, 20:4, 22:5, and 22:6) could have compensated
for the loss of (18:2)4 CL thus preserving the local envir-
onment for normal mitochondrial function. Indeed, cal-
cium retention, cytochrome c sequestration, membrane
fusion and fission, respiratory chain, and apoptosis are all
dependent on CL content [9–12].
Because one of the controversial molecular mechanisms
of anthracycline-induced cardiotoxicity is oxidative stress
[42–44], we used a recently developed two-dimensional
LC-MS/MS [28, 29] to analyze oxidized CL. Various
conditions can cause cardiolipin oxidation, among them
cytochrome c/H2O2 and oxygenated Fe2
+ buffer (hydroxyl
radical generated by the Fenton and the Haber-Weiss)
reactions [28, 31, 45]. As doxorubicin leads to accumula-
tion of iron in the mitochondria [46], we used ferrous sul-
fate buffer for CLox-positive control. We did not observe
a high level of CLox in doxorubicin-treated males. Indeed,
around 0.05 % of (18:2)4 containing 4 to 7 oxygens was
detected. This result is in accordance with our previous
data showing no obvious global protein oxidation [5].
Obviously, oxidative stress is species-, time-, and drug
concentration-dependent, in other words model-dependent
[42–44, 46–48]. It seems that while high level of CLox has
Fig. 6 Fatty acid synthesis and cardiolipin homeostasis pathway analysis in males and females treated with doxorubicin. Gene expression analysis
in ventricle of 7 weeks doxorubicin-treated rats: Cd36, Acsl1, Cds1, Cds2, Crsl1, Tafazzin, Alcat1, Δ6-desaturase, Δ5-desaturase, and Elongases 2 and 5
(mean ± SEM of four rats per group)
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been observed in acute stress, level of CLox could be mod-
erate in chronic stress. After traumatic brain injury in post-
natal day 17 rats, the content of oxidized CL species
increased 20-fold at the expense of non-oxidized species
[49]. Chronic western diet of LDLR−/− (low density lipo-
protein receptor knockout) mice during 16 weeks induced
a 0.1 % significant increase of oxidized cardiolipin in the
liver mitochondria [50]. Therefore, we can hypothesize that
either chronic doxorubicin treatment with moderate doses
induces only low levels of CLox or that CLox may be pro-
duced early after injection but rapidly discarded to avoid
mitochondrial dysfunction.
In DOXO-treated males but not females, we observed
an early decrease in PGC-1β [5]. Recently, PGC-1α/β,
key transcriptional regulators of mitochondrial metabol-
ism, has been implicated in the regulation of cardiac
phospholipid biosynthesis [51]. Despite grossly normal
cardiac function of PGC-1α/β heart−/−, mitochondrial
ultrastructure abnormalities were observed [51]. PGC-
1α/β hearts−/− were characterized by normal level of
MLCL but reduced levels of most PE, PC, and CL and a
decreased level of CDP-diacylglycerol synthase Cds-1
showing that Cds-1 was a direct target of PGC-1. We
observed that Cds-1 was highly downregulated after
doxorubicin in both sexes and even in basal level for
females. In PGC-1α/β heart −/−, a reduction in PL-
containing 22:5 and 22:6 acyl chains was observed [51]
whereas in our model an increase was noticed. Thus, PL
remodelling in DOXO cardiotoxicity can hardly be
explained by PGC-1 downregulation.
It has been proposed that remodelling of CL can be
linked to poly-unsaturated fatty acid metabolism [32].
An interesting feature of female cardiac PLs is the pres-
ence of species with long acyl chains not only in CL but
in other PL classes. Elevated long-chain omega 3 fatty
acids in females under the same diet than males have
been reported in numerous studies [52]. This sex differ-
ence has been linked in part to estrogens, FA remodelling
enzymes, and peroxisome proliferator-activated receptor
alpha (PPARα) activity. In the liver, but not the heart, gene
expression of Δ6- and Δ5-desaturases and Elongases,
enzymes involved in the production of long-chain poly-
unsaturated FAs from 18:2, is greater in females [53]. In
our study, supply of essential fatty acid (α-linolenic acid
18:3 and linoleic acid 18:2) from diet was the same for
males and females treated or not with doxorubicin. How-
ever, in males, the specific decrease of Elongase5 and the
tendency to decrease for Δ6-desaturase were more sug-
gestive of impaired rather than improved production of
long-chain fatty acids from α-linolenic acid 18:3 and lino-
leic acid 18:2. Expression of these enzymes has been
shown to be under the control of an estrogen-mediated
PPARα activation. Interestingly, we have previously ob-
served that PPARα was less downregulated in
doxorubicin-treated females [5]. Regarding FA pathway,
the gene expression of Cd36, a regulator of the first step,
i.e., uptake of FA across the plasma membrane, remained
stable after DOXO in both sexes. However, Acsl1, the
major acyl-CoA synthethase isoform in the heart that con-
verts long-chain fatty acid into acyl-CoA thioesters plus
AMP was also less downregulated in females. Interest-
ingly, ACSL1 in the liver was described to play an import-
ant role in directing FA into pathways of phospholipid
synthesis and away from cholesterolesterification and β-
oxidation [54]. After doxorubicin treatment, we have
shown that multiple steps of β-oxidation (MCAD and
CPT1) were downregulated similarly in both sexes [5]. It
appeared that FA pathway of PL synthesis rather than β-
oxidation seems more preserved in females that have a
better cardiac function (Additional file 1: Figure S3). In
line with all these results, we have previously observed
that females treated with doxorubicin have intensified liver
hepatomegaly and elevated circulating level of triglycer-
ides compared to males [5]. Similar to our results, Julicher
et al. also observed a more important hepatomegaly after
doxorubicin treatment in females [55]. We can hypothesize
that a protective mechanism linked to lipid metabolism is
activated only in females.
Finally, sex difference in cardiotoxicity of doxorubicin
has not been extensively studied. However, some clinical
and experimental studies have observed that females
develop less unwanted cardiac side effects after doxorubi-
cin treatment than males [5, 55–59]. The mechanism of
female cardioprotection is far from being completely
understood. Among the proposed pathways involved were
higher oxidative defenses capacity in females [57], in-
creased level of cardiac mast cells activity in males [59],
and better mitochondrial metabolism and bioenergetic
protection in females [5]. Interestingly, interactions be-
tween doxorubicin and negatively charged phospholipid
and more specifically cardiolipin have been demonstrated
by several groups [2, 4]. Cardiolipins are essential for re-
spiratory chain functioning, ATP generation, and en-
ergy transfer. The heart is a highly energy-consuming
organ, and cardiac contraction is linearly related to
mitochondrial respiration thus anthracycline-mediated car-
diolipin alterations would be a determinant factor in mito-
chondrial alterations and cardiotoxicity [5, 37, 44, 60]. We
have now shown that cardiolipin remodelling is probably
important in the sexual dimorphism of doxorubicin-
induced cardiotoxicity. Additional studies are necessary to
better understand the roles of lipids in the anthracycline
cardiotoxicity and sex differences.
Conclusions
In this study, we showed that (1) a decrease of global
phospholipids was only observed in doxorubicin-treated
males, (2) the level of PE and PC species containing long
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acyl chains was more important in females than in males
with or without doxorubicin, (3) doxorubicin mediated a
decline of PE and PC containing one linoleoyl acyl chain
in both sexes, (4) significant loss of L4CL was comparable
in treated males and females while (18:2)3 MLCL
remained stable, (5) the level of most long-chain CL and
MLCL species was more important specifically for
doxorubicin-treated females, (6) CL oxidation did not ap-
pear to be a key parameter in this chronic treatment, and
(7) sex differences were found in gene expression of FA
biosynthesis after doxorubicin treatment. Altogether, the
cardiac phospholipidomic analysis has highlighted an in-
teresting sex-specific PL molecular species remodelling
(Table 2).
This study has unraveled a significant sexual dimorph-
ism in the cardiac phospholipid content after a chronic
cardiotoxic stress. A cause-and-effect relationship be-
tween altered phospholipid content and sex differences
in doxorubicin-induced cardiotoxicity remains to be
established. Further studies are needed to decode the
male-specific cardiotoxicity to be able to develop new
therapeutic strategies.
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